tailieunhanh - Báo cáo y học: "ahead at the potential benefits of biotechnology-derived allergen therapeutics"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: ahead at the potential benefits of biotechnology-derived allergen therapeutics. | Clinical and Molecular Allergy BioMed Central Commentary Looking ahead at the potential benefits of biotechnology-derived allergen therapeutics Jason Behrmann Open Access Address Programmes de bioéthique Université de Montreal . 6128 succursale centre-ville Montreal Quebec H3C 3J7 Canada Email Jason Behrmann - Corresponding author Published 4 July 2007 Clinical and Molecular Allergy 2007 5 3 doi 1476-7961-5-3 Received 17 April 2007 Accepted 4 July 2007 This article is available from http content 5 1 3 2007 Behrmann licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract While biotechnology-derived allergen therapeutics show promise in improving the safety of immunotherapy they may prove to have additional benefits in comparison to conventional allergenic extracts that deserve commentary. These issues range from product stability and compatibility to medical practice issues which will be the focus of this article. Background Allergies or hyperimmune responses to ordinary entities in our environment are extremely common chronic pathological conditions that affect 10 to 25 of the population 1 2 and have significant impacts on productivity quality of life issues and costs towards the administration of health services 3 . Common practices for ameliorating allergy symptoms include allergen avoidance allergen elimination pharmacotherapy such as the administration of anti-histamines and allergen-specific immunotherapy. Allergen-specific immunotherapy SIT was developed in 1911 4 and is the only treatment that attends to the root cause rather than the clinical symptoms of allergic reactions. The most common method of SIT employs the subcutaneous injection of .